PROCEPT BioRobotics Corporation Operating Income
PROCEPT BioRobotics Corporation (PRCT) reported Operating Income of -$27.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- PROCEPT BioRobotics Corporation operating income (loss) for the quarter ending 2026-06-30 was -$27.39M.
- PROCEPT BioRobotics Corporation operating income (loss) for the quarter ending 2026-03-31 was -$32.61M.
- PROCEPT BioRobotics Corporation operating income (loss) for the quarter ending 2025-12-31 was -$31.04M.
- PROCEPT BioRobotics Corporation operating income (loss) for the quarter ending 2025-09-30 was -$23.19M.
- PROCEPT BioRobotics Corporation operating income (loss) for fiscal 2025 was -$103.86M.
- PROCEPT BioRobotics Corporation operating income (loss) for fiscal 2024 was -$96.61M.
- PROCEPT BioRobotics Corporation operating income (loss) for fiscal 2023 was -$109.17M.
- PROCEPT BioRobotics Corporation operating income (loss) for fiscal 2022 was -$80.72M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.39M 10-Q · filed 2026-08-05 | -$60.00M 10-Q · filed 2026-08-05 | -$91.04M derived: sum of 3 quarters · filed 2026-08-05 | -$114.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$32.61M 10-Q · filed 2026-04-30 | -$63.65M derived: sum of 2 quarters · filed 2026-04-30 | -$86.84M derived: sum of 3 quarters · filed 2026-04-30 | -$109.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$31.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$54.23M derived: sum of 2 quarters · filed 2026-02-26 | -$76.42M derived: sum of 3 quarters · filed 2026-08-05 | -$103.86M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$23.19M 10-Q · filed 2025-11-05 | -$45.38M derived: sum of 2 quarters · filed 2026-08-05 | -$72.82M 10-Q · filed 2025-11-05 | -$92.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$22.19M 10-Q · filed 2026-08-05 | -$49.63M 10-Q · filed 2026-08-05 | -$69.34M derived: sum of 3 quarters · filed 2026-08-05 | -$91.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$27.44M 10-Q · filed 2026-04-30 | -$47.15M derived: sum of 2 quarters · filed 2026-04-30 | -$69.58M derived: sum of 3 quarters · filed 2026-04-30 | -$96.40M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$19.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$42.14M derived: sum of 2 quarters · filed 2026-02-26 | -$68.97M derived: sum of 3 quarters · filed 2026-02-26 | -$96.61M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$22.43M 10-Q · filed 2025-11-05 | -$49.26M derived: sum of 2 quarters · filed 2025-11-05 | -$76.90M 10-Q · filed 2025-11-05 | -$106.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$26.83M 10-Q · filed 2025-08-07 | -$54.48M 10-Q · filed 2025-08-07 | -$84.03M derived: sum of 3 quarters · filed 2026-02-26 | -$109.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$27.65M 10-Q · filed 2025-05-02 | -$57.21M derived: sum of 2 quarters · filed 2026-02-26 | -$82.81M derived: sum of 3 quarters · filed 2026-02-26 | -$108.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$29.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$55.17M derived: sum of 2 quarters · filed 2026-02-26 | -$80.79M derived: sum of 3 quarters · filed 2026-02-26 | -$109.17M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$25.61M 10-Q · filed 2024-10-28 | -$51.23M derived: sum of 2 quarters · filed 2024-10-28 | -$79.61M 10-Q · filed 2024-10-28 | -$104.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$25.63M 10-Q · filed 2024-08-02 | -$54.00M 10-Q · filed 2024-08-02 | -$79.04M derived: sum of 3 quarters · filed 2025-02-27 | -$101.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$28.38M 10-Q · filed 2024-05-02 | -$53.42M derived: sum of 2 quarters · filed 2025-02-27 | -$75.52M derived: sum of 3 quarters · filed 2025-02-27 | -$93.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$25.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$47.15M derived: sum of 2 quarters · filed 2025-02-27 | -$65.02M derived: sum of 3 quarters · filed 2025-02-27 | -$80.72M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$22.11M 10-Q · filed 2023-11-02 | -$39.98M derived: sum of 2 quarters · filed 2023-11-02 | -$55.68M 10-Q · filed 2023-11-02 | -$72.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$17.88M 10-Q · filed 2023-07-28 | -$33.58M 10-Q · filed 2023-07-28 | -$50.41M derived: sum of 3 quarters · filed 2024-02-28 | -$63.21M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$15.70M 10-Q · filed 2023-05-04 | -$32.53M derived: sum of 2 quarters · filed 2024-02-28 | -$45.33M derived: sum of 3 quarters · filed 2024-02-28 | -$58.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$16.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$29.63M derived: sum of 2 quarters · filed 2024-02-28 | -$42.82M derived: sum of 3 quarters · filed 2024-02-28 | -$54.16M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$12.80M 10-Q · filed 2022-11-04 | -$25.99M derived: sum of 2 quarters · filed 2022-11-04 | -$37.33M 10-Q · filed 2022-11-04 | -$50.54M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | -$13.19M 10-Q · filed 2022-08-05 | -$24.54M 10-Q · filed 2022-08-05 | -$37.74M derived: sum of 3 quarters · filed 2022-08-05 | -$48.72M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$11.34M 10-Q · filed 2022-05-06 | -$24.55M derived: sum of 2 quarters · filed 2022-05-06 | -$35.53M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | -$13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$24.18M derived: sum of 2 quarters · filed 2022-03-22 | -$47.80M 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$10.98M 10-Q · filed 2021-11-05 | -$34.59M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |